TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial

Παρόμοια τεκμήρια

• Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
  ανά: Constantine, Ginger D., κ.ά.
  Έκδοση: (2019)
• SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
  ανά: Constantine, Ginger, κ.ά.
  Έκδοση: (2019)
• 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
  ανά: Kaunitz, Andrew M., κ.ά.
  Έκδοση: (2020)
• Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
  ανά: Lobo, Rogerio A., κ.ά.
  Έκδοση: (2019)
• Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
  ανά: Simon, James A., κ.ά.
  Έκδοση: (2019)